NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Has Average Price Target of $7.33

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $7.33.

NMTC has been the topic of several recent research reports. Maxim Group set a $5.00 target price on shares of NeuroOne Medical Technologies and gave the company a “buy” rating in a research report on Friday, August 14th. Weiss Ratings cut shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st.

Insider Activity

In other NeuroOne Medical Technologies news, insider David Wambeke purchased 33,333 shares of the stock in a transaction dated Thursday, August 27th. The stock was bought at an average price of $2.01 per share, for a total transaction of $66,999.33. Following the transaction, the insider directly owned 199,999 shares in the company, valued at $401,997.99. This represents a 20.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Bard Associates Inc. acquired a new stake in shares of NeuroOne Medical Technologies during the second quarter worth $929,000. BlackRock Inc. bought a new stake in NeuroOne Medical Technologies in the second quarter valued at about $76,000. Finally, Susquehanna International Group LLP acquired a new position in NeuroOne Medical Technologies in the second quarter valued at about $41,000. Institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Price Performance

NMTC opened at $0.76 on Friday. NeuroOne Medical Technologies has a fifty-two week low of $0.75 and a fifty-two week high of $6.12. The firm’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $3.01. The company has a market capitalization of $6.89 million, a P/E ratio of -0.80 and a beta of 0.95.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The business had revenue of $1.97 million during the quarter, compared to the consensus estimate of $2.17 million. NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. On average, equities research analysts expect that NeuroOne Medical Technologies will post -0.39 EPS for the current fiscal year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is a medical device company focused on developing thin-film electrode technology for neurological applications. Its products are designed to support the diagnosis, monitoring and treatment of disorders affecting the brain and nervous system. The company’s product portfolio includes the Evo cortical and stereoelectroencephalography (sEEG) electrode systems, which are used by clinicians to record electrical activity in the brain and help evaluate patients with conditions such as epilepsy.